Systemic lupus erythematosus, a disease associated with low levels of clusterin/ApoJ, an antiinflammatory protein

Journal of Rheumatology

Volumn 26, Issue 3, 1999, Pages 597-603

  Newkirk, Marianna M ^a   Apostolakos, Persefoni ^a   Neville, Carolyn ^a   Fortin, Paul R ^a  

^a MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

Alopecia; Arthritis; Clusterin; Proteinuria; Systemic lupus erythematosus

Indexed keywords

ANTIINFLAMMATORY AGENT; CLUSTERIN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; PREDNISONE;

ALOPECIA; ARTHRITIS; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEINURIA; SKIN ULCER; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA;

AUTOANTIBODIES; CLUSTERIN; COHORT STUDIES; COMPLEMENT INACTIVATOR PROTEINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYCOPROTEINS; HUMANS; IMMUNOBLOTTING; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MOLECULAR CHAPERONES;

EID: 0033051213     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Worrall JG, Snaith ML, Batchelor JR, Isenberg DA. SLE: a rheumatological view. Analysis of the clinical features, serology and immunogenetics of 100 SLE patients during long-term follow-up. Q J Med 1990;74:319-30.
2. Mills JA. Systemic lupus erythematosus. N Engl J Med 1994;330:1871-9.
3. Casciola-Rosen LA, Anhalt G, Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptolic keratinocytes. J Exp Med 1994;179:1317-30.
4. French LE, Wohlwend A, Sappino A-P, Tschopp J, Schifferli JA. Human clusterin gene expression is confined to surviving cells during in vitro programmed cell death. J Clin Invest 1994; 93:877-84.
5. Rosenberg ME, Silkensen J. Clusterin: physiologic and pathophysiologic considerations. Int J Biochem Cell Biol 1995;27:633-45.
6. Tschopp J, Chonn A, Hertig S, French LE. Clusterin, the human apolipoprotein and complement inhibitor, binds to complement C7, C8ß, and the b domain of C9. J Immunol 1993;151:2159-65.
7. Wilson MR, Easterbrook-Smith SB. Clusterin binds by a multivalent mechanism to the Fc and Fab regions of IgG. Biochim Biophys Acta 1992;1159:319-26.
8. Reddy KB, Jin G, Karode MC, Harmony JAK, Howe PH. Transforming growth factor ß-induced nuclear localization of apolipoprotein J/clusterin in epithelial cells. Biochemistry 1996;35:6157-63.
9. Reddy KB, Karode MC, Harmony JAK, Howe PH. Interaction of transforming growth factor beta receptors with apolipoprotein J/clusterin. Biochemistry 1996;35:309-14.
10. Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in SLE. Arthritis Rheum 1989;32:1107-18.
11. Hogasen K, Mollnes TE, Tschopp J, Harboe M. Quantitation of vitronectin and clusterin. Pitfalls and solutions in enzyme immunoassays for adhesive proteins. J Immunol Methods 1993;160:107-15.
12. Laemmli UK. Cleavage of structural proteins during the assembly of the head bacteriophage T4. Nature 1970;227:680-5.
13. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 1979;76:4350-4.
14. Gutacker C, Flach R, Diel P, Klock G, Koch-Brandt C. Multiple signal transduction pathways regulate clusterin (GP 80) gene expression in MDCK cells. J Mol Endocrin 1996;17:109-19.
15. Tycko B, Feng L, Nguyen L, et al. Polymorphisms in the human apolipoprotein-J/clusterin gene: ethnic variation and distribution in Alzheimer's disease. Hum Genet 1996;98:430-6.
16. Saunders JR, Aminian A, McRae JL, et al. Clusterin depletion enhances immune glomerular injury in the isolated perfused kidney. Kidney Int 1994;45:817-27.
17. Jenkins SH, Stuart WD, Bottoms LA, Harmony JAK. Quantitation of plasma Apolipoprotein J. Methods Enzymul 1996;263:309-16.
18. Fink TM, Zimmer M, Tschopp J, Etienne J, Jenne DE, Lichter P. Human clusterin (CL1) maps to 8p21 in proximity to lipoprotein lipase (LPL) gene. Genomics 1993;16:526-8.
19. Howard PF, Hochberg MC, Bias WB, Arnett FC, McLean RH. Relationship between C4 null genes. HLD-D region antigens and genetic susceptibility to systemic lupus erythematosus in Caucasians and black Americans. Am J Med 1986;81:187-93.
20. Davies EJ, Snowden N, Hillarby MC, et al. Mannose-binding protein gene polymorphism in systemic lupus erythematosus. Arthritis Rheum 1995;38:110-4.
21. Duits AJ, Botsma H, Derksen RHWM, et al. Skewed distribution of IgG Fc receptor Ha (CD32) polymorphism is associated with renal disease in systemic lupus erythematosus patients. Arthritis Rheum 1995;39:1832-6.
22. Tsao BP, Cantor RM, Kalunian KC, et al. Evidence for linkage of a candidate chromosome 1 region to human systemic lupus erythematosus. J Clin Invest 1997;99:725-31.
23. Seiberg M. Marthinuss J. Clusterin expression within skin correlates with hair growth. Develop Dynamics 1995;202:294-301.
24. French LE, Polla LL, Tschopp J, Schifferli JA. Membrane attack complex deposits in skin are not always accompanied by S-protein and clusterin. J Invest Dermatol 1992;98:758-63.
25. Fortin PR, Abrahamowicz M, Danoff D. Small changes in outpatient lupus activity are better detected by clinical instruments than by laboratory tests. J Rheumatol 1995;22:2078-83.
26. Petri M, Genovese M, Engle E, Hochberg M. Definition, incidence and clinical description of flare in systemic lupus erythematosus. A prospective cohort study. Arthritis Rheum 1991;34:937-44.
27. Buyon JP, Tamerius J, Belmont HM, Abramson SM. Assessment of disease activity and impending flare in systemic lupus erythematosus. Comparison of the use of complement split products and conventional measurements of complement. Arthritis Rheum 1992;35:1028-37.
28. Esdaile JM, Joseph L, Mackenzie T, Danoff D, Li Y, Abrahamowicz M. Laboratory tests as predictors of "flare" in systemic lupus erythematosus [abstract]. Arthritis Rheum 1994;37 Suppl:S133.
29. Zonana-Nacach A, Salas M, de Lourdes Sanchez M, et al. Measurement of clinical activity of systemic lupus erythematosus and laboratory abnormalities: A 12-month prospective study. J Rheumatol 1995;22:45-9.
30. Hogasen K, Mollnes TE, Brandtzaeg P. Low levels of vitronectin and clusterin in acute meningococcal disease are closely associated with formation of the terminal complement complex and the vitronectin-thrombin-antithrombin complex. Infect Immun 1994;62:4874-80.
31. Hogasen K, Homann C, Mollnes TE, et al. Serum clusterin and vitronectin in alcoholic cirrhosis. Liver 1996;16:140-6.
32. Hogasen K, Mollnes TE, Harboe M, Gotze O, Hammer HB, Oppermann M. Terminal complement pathway activation and low lysis inhibitors in rheumatoid arthritis synovial fluid. J Rheumatol 1995;22:24-8.
33. French LE, Tschopp J, Schifferli JA. Clusterin in renal tissue: preferential localization with the terminal complement complex and immunoglobulin deposits in glomeruli. Clin Exp Immunol 1992;88:389-93.